✦ LIBER ✦

72 POSTER Phase I, safety, pharmacokinetic and biomarker study of telatinib (BAY 57-9352), an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors

✍ Scribed by H. Gelderblom; J. Verweij; N. Steeghs; E. de Koning; A. van Erkel; L. van Doorn; M. Zuehlsdorf; P. Rajagopalan; O. Christensen; F. Eskens

Book ID: 118623701
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 57 KB
Volume: 4
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(06)70078-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

41 POSTER Clinical and biomarker respons

41 POSTER Clinical and biomarker responses in a phase I study of BAY 57 9352 – a VEGFR-2 inhibitor – administered as continuous dosing in patients with advanced solid tumors

✍ D. Strumberg; O. Christensen; R. Strecker; M.E. Scheulen; A. Frost; P. Rajagopal 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 58 KB

38 POSTER Phase I and pharmacological st

38 POSTER Phase I and pharmacological study of KRN951, a potent VEGFR tyrosine kinase inhibitor given in a 4 week on, 2 week off schedule in patients with advanced solid tumors

✍ F.A.L.M. Eskens; M.J.A. de Jonge; L. van Doorn; T. Isoe; K. Hayashi; S. Hussain; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 53 KB

137 A phase I study of an oral vascular

137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors

✍ Tolcher, A.; O'Leary, J.J.; DeBono, J.; Molpus, K.; Woodard, C.; Warnat, M.; Lia 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 148 KB

282 POSTER Preliminary results of a Phas

282 POSTER Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors

✍ P. Schöffski; H. Dumez; S.F. Jones; C. Fowst; P. Gerletti; H. Xu; J. Jakubczak; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 64 KB

A Phase I study to assess the safety, to

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

✍ J. R. Infante; R. Kurzrock; J. Spratlin; H. A. Burris; S. G. Eckhardt; J. Li; K. 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 338 KB

585 POSTER Phase I study of the safety a

585 POSTER Phase I study of the safety and pharmacokinetics of an oral, film-coated (FC) tablet of CP-868,596, a PDGFR inhibitor, in patients with advanced cancers

✍ L. Lewis; N. Reddy; F. Guo; K.J. Pierce; A.J. Olszanski; S. Balan 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 60 KB